Monopar Therapeutics Inc.
MNPR
$113.04
$2.632.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -116.56% | -48.31% | 52.40% | -163.56% | -43.04% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -39.21% | -27.70% | -91.96% | 452.08% | 254.37% |
| Change in Net Operating Assets | 604.03% | 88.90% | -64.85% | 682.02% | 164.58% |
| Cash from Operations | -201.41% | 38.66% | -68.64% | -94.74% | 35.75% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 246.63% | -1,613.81% | -333.72% | -315.68% | 49,570.83% |
| Cash from Investing | 246.63% | -1,613.81% | -333.72% | -315.68% | 49,570.83% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 61.70% | -- | -- | -- | 4,600.00% |
| Repurchase of Common Stock | -103.67% | -52.71% | -475.04% | -214,333.33% | -3,116.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -104.36% | -73.03% | -100.69% | 560,049.09% | -3,100.00% |
| Foreign Exchange rate Adjustments | -173.08% | -31,500.00% | 2,718.42% | -91.11% | -273.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 201.91% | -52.16% | -265.45% | 88,452.10% | 87.59% |